<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Uterine Cancer PDX Models

Patient-derived xenograft (PDX) models display a true representation of the human heterogeneity of gynecologic malignancies and provide the most accurate approach to predicting an agents efficacy prior to entering the clinic. The Crown Bioscience uterine cancer PDX collection consists of several models including ER+ and estrogen dependent models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
UT14024 Uterine Cancer NA Uterine Carcinoma. Pathol comment: C/W DIAGNOSIS. APPROXIMATELY 50% OF THE TISSUE INVOLVED MALIGNANT TUMOR IN SECTIONS EXAMINED. 30% NECROTIC. MALIGNANT CELLS PRESENT IN CYTOSPIN PREP. CLICK TO VIEW
UT14026 Uterine Cancer NA Right frontal brain tumor, metastatic, high grade adenocarcinoma CLICK TO VIEW
UT3617 Uterine Cancer Endometrial Body and fundus of uterus: endometrial glandular adenocarcinoma, grade II, infiltrative growth CLICK TO VIEW
UT3618 Uterine Cancer NA NA CLICK TO VIEW
UT3759 Uterine Cancer Endometrial Uterus: endometrioid adenocarcinoma, moderately to well differentiated CLICK TO VIEW
UT3778 Uterine Cancer Endometrial Uterus: endometrioid adenocarcinoma, grade II, infiltrating left adnexa of uterus CLICK TO VIEW
UT5317 Uterine Cancer Endometrial, (ER+) endometrial carcinoma. Pathol comment: c/w diagnosis. approximately 60% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
UT5318 Uterine Cancer Endometrial, (ER-) endometrial carcinomarecurrent papillary serous carcinoma. Pathol comment: c/w referring diagnosis. rare malignant tumor cells present in sections examined. malignant tumor cells present in cytospin prep. CLICK TO VIEW
UT5319 Uterine Cancer Endometrial, (ER+) endometrial carcinomametastatic endometrioid adenocarcinoma. Pathol comment: c/w diagnosis. approximately 70% of the tissue involved malignant tumor in sections examined. 80% necrotic. malignant cells present in cytospin prep. CLICK TO VIEW
UT5320 Uterine Cancer Endometrial, (ER-) endometrial carcinomametastatic carcinoma, pd. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved malignant tumor in sections examined. 70% necrotic. malignant cells present in cytospin prep. CLICK TO VIEW
UT5321 Uterine Cancer Endometrial, (ER+) endometrial carcinoma metastatic endometrioid adenocarcinoma, pd. Pathol comment: c/w diagnosis. approximately 50% of the tissue involved by malignant tumor in sections examined. approximately 80% malignant tumor cells present in cytospin preparation. CLICK TO VIEW
UT5322 Uterine Cancer Endometrial primary endometrial cancer + either primary ovary cancer or mets to ovary grade 2 CLICK TO VIEW
UT5324 Uterine Cancer ADC metastatic, stage iv, poorly differentiated uterine adenocarcinoma, refractorypoorly differentiated carcinoma CLICK TO VIEW
UT5325 Uterine Cancer ADC metastatic, stage iv, poorly differentiated uterine adenocarcinoma, refractorypoorly differentiated carcinoma CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login